Figure 1

Novel European Asiatic Clinical, Laboratory, Molecular and Pathobiological (2015-2020 CLMP) criteria for JAK2V617F trilinear polycythemia vera (PV), JAK2exon12 PV and JAK2V617F, CALR and MPL515 thrombocythemias: From Dameshek to Constantinescu-Vainchenker, Kralovics and Michiels

Jan Jacques Michiels*, King H Lam, Fibo Ten Kate, Dong-Wook Kim, Myungshin Kim, Vasily Shuvaev, Francisca Valster, Vincent Potters, Wilfried Schroyens, Mihaela Andreescu, Adrian Trifa, Achille Pich and Hendrik De Raeve

Published: 03 April, 2020 | Volume 3 - Issue 1 | Pages: 001-020


Figure 1:

Upper part: The discovery by Constantinescu & Vainchenker of the JAK2V617F somatic mutation as the cause of trilinear myeloproloferative neoplasms and the sequential occurrence of heterozygous JAK2V617F mutation in essential thrombocythemia (ET) and homozygous JAK2V617F mutation in trilinear polycythemia vera (PV) which does explain the occurrence of three sequential phenotypes of ET, PV and myelofibrosis (MF) during life long follow-up in the studies of Dameshek and Michiels. Lower part: Concept of Michiels & De Raeve on the dynamics of the JAK2V617F disease processes in trilinear MPN ranged from normocellular ET and prodromal PV mimicking ET with normal erythrocyte count below 5.8x1012/L to defintive increase in peripheral blood erythrocytes above 5.8x1012/L) in PV followed by masked PV, advanced PV complicated by fibrosis and splenomegaly, spentphase PV and blast transformation of post - PV myelofibrosis. Designedby Michiels 2020.

Read Full Article HTML DOI: 10.29328/journal.ijbmr.1001011 Cite this Article Read Full Article PDF

More Images

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?